Single answer
Is Atossa Therapeutics Inc (ATOS) a buy or sell?
4starter turns market data into one clear verdict you can act on.
Create a free account to save tickers and track your signals.
Log in to turn on watchlist alerts.
Decision snapshot
Everything you need to act fast, in one glance.
What is the conclusion?
Right now our advanced algorithms say:
Do analysts agree?
We compare consensus targets with today's price.
Consensus target for Atossa Therapeutics Inc is $10.00, which is $5.59 (126.76%) above the current price today's price.
Low target: $10.00 | High target: $10.00
Latest analyst updates
Recent rating and price target changes for this stock.
Company snapshot
A quick overview of the business and its public profile.
Atossa Therapeutics Inc operates as a clinicalstage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States The companys lead drug candidate is oral Zendoxifen an active metabolite of tamoxifen which is in Phase II clinical trials to treat and prevent breast cancer It also develops immunotherapychimeric antigen receptor therapy programs The company was formerly known as Atossa Genetics Inc and changed its name to Atossa Therapeutics Inc in January 2020 Atossa Therapeutics Inc was founded in 2008 and is based in Seattle Washington
Website: https://www.atossatherapeutics.com
Rates and inflation backdrop
US inflation for January 2026 was 0.17%. Over the last 12 months, inflation is 2.83%. The 10-year yield is 4.04 and is down -0.110 over the last 30 days.
Inflation sensitivity
Debt ratio: 0.00. Cash flow to debt ratio: 0.00. Net profit margin: 0.00%. Inflation risk score: medium (0.60/1).
Dividend history check
We cannot find any recorded dividends paid in our systems.
Trading liquidity
Yes, the average daily trading liquidity for Atossa Therapeutics Inc is $1.1M. You should therefore be able to get in and out of your positions relatively fast.
10-year return check
On Atossa Therapeutics Inc, 2016-02-26 had a stock price of $75.60. If you invested back then, your return now would be a loss of $71.33 per share or 94.35%.
Why this answer
We combine price momentum, volatility, and trend signals to simplify the decision to one word.
Signal engine scans price, trend, and momentum indicators.
Targets and sentiment are checked against the live quote.
We keep the output simple: buy, sell, or hold.
Analyst consensus
How Wall Street targets compare to today's price.